These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34152670)

  • 1. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
    Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
    Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.
    Stingeni L; Bianchi L; Antonelli E; Caroppo ES; Ferrucci SM; Ortoncelli M; Fabbrocini G; Nettis E; Schena D; Napolitano M; Gola M; Bonzano L; Rossi M; Belloni Fortina A; Balato A; Peris K; Foti C; Guarneri F; Romanelli M; Patruno C; Savoia P; Fargnoli MC; Russo F; Errichetti E; Bianchelli T; Bianchi L; Pellacani G; Feliciani C; Offidani A; Corazza M; Micali G; Milanesi N; Malara G; Chiricozzi A; Tramontana M; Hansel K;
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1292-1299. PubMed ID: 35412683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
    Napolitano M; Fabbrocini G; Potestio L; Fontanella G; Picone V; Bennardo L; Scalvenzi M; Patruno C
    Dermatol Ther; 2022 Aug; 35(8):e15588. PubMed ID: 35569129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
    J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
    Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life experience in the effectiveness, impact on quality of life and safety of dupilumab treatment in patients with moderate to severe atopic dermatitis in the Czech Republic.
    Tánczosová M; Kojanová M; Arenbergerová M; Arenberger P; Doležal T; Štrosová D; Fialová J; Gkalpakiotis S
    Cent Eur J Public Health; 2022 Mar; 30(1):46-50. PubMed ID: 35421298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
    Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
    Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
    Chia SY; Wee LWY; Koh MJA
    Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab.
    Vanessa M; Elia E; Federica V; Edoardo C; Chiara A; Francesca G; Paola S
    Dermatol Ther; 2022 Jul; 35(7):e15573. PubMed ID: 35535633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study.
    Pagan AD; David E; Ungar B; Ghalili S; He H; Guttman-Yassky E
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2378-2385. PubMed ID: 35753667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
    Patruno C; Fabbrocini G; Lauletta G; Boccaletti V; Colonna C; Cavalli R; Neri I; Ortoncelli M; Schena D; Stingeni L; Hansel K; Piccolo V; Di Brizzi V; Potenza C; Tolino E; Bianchi L; Manti S; De Pasquale R; Di Lernia V; Caminiti L; Galli E; Coppo P; Chiricozzi A; De Simone C; Guerriero C; Amoruso FG; Provenzano E; Leonardi S; Licari A; Marseglia GL; Palermo A; Di Pillo S; Russo D; Moschese V; Patella V; Peduto T; Ferreli C; Zangari P; Veronese F; Berti SF; Gruber M; Pezzolo E; Termine S; Satta R; Dragoni F; Esposito M; Fargnoli MC; Chiodini P; Vallone Y; di Vico F; Picone V; Napolitano M
    J Dermatolog Treat; 2023 Dec; 34(1):2246602. PubMed ID: 37580895
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.
    Deng S; Wang H; Chen Q; Chen X; Song X; Chen S; Kong M; Song Z
    Arch Dermatol Res; 2024 May; 316(6):304. PubMed ID: 38819652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Salman A; Apti Sengun Ö; Aktas M; Taşkapan O
    Dermatol Ther; 2022 Jan; 35(1):e15192. PubMed ID: 34743366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China.
    Yang N; Ye Y; Shao J; Wu H; Xu Q; Zhu J; Liu J; Li Z
    Dermatitis; 2024; 35(S1):S39-S46. PubMed ID: 36800177
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study.
    Hu YQ; Zhang JZ; Zhao Y
    Dermatology; 2024; 240(4):589-596. PubMed ID: 38797168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.